Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology (AAD) Annual Meeting
“We are excited to present new clinical data for our immunology portfolio at AAD Annual Meeting.
- “We are excited to present new clinical data for our immunology portfolio at AAD Annual Meeting.
- The high-concentration (40 mg/0.4 mL) formulation of prefilled syringe and prefilled autoinjector of HADLIMA was approved in August 2022.
- The study showed that efficacy, safety, and immunogenicity between the three arms were comparable up to Week 52.
- Details of the Samsung Bioepis’ abstracts are as follows:
Clinical Similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis: Randomized, Double-blind, Phase III, 52-Week Results